ZyVersa Therapeutics secures $2.0 million in cash proceeds through warrant inducement agreement.

ZyVersa Therapeutics, Inc. has entered into a warrant inducement agreement with an institutional investor, resulting in gross cash proceeds of approximately $2.0 million. The investor exercised Series A-2 and A-3 warrants at a reduced price of $0.67, receiving new Series A-4 warrants in return. These new warrants will allow the purchase of up to 6,124,930 shares of common stock. The closing of this transaction is expected on July 9, 2025. A.G.P./Alliance Global Partners served as the exclusive financial advisor for this agreement. The Company will use the net proceeds for working capital and general corporate purposes, as stated by ZyVersa Therapeutics, Inc.

Read more at GlobeNewswire: ZyVersa Therapeutics Announces a Warrant Inducement